Ahn IE, Brown JR. Targeting Bruton’s tyrosine kinase in CLL. Front Immunol 2021;12:687458. Abstract
Allan JN et al. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 2022;107(4):984-7. Abstract
Davids MS et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood 2022;139(5):686-9. Abstract
Gadi D et al. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia 2022;36(3):723-32. Abstract
Mato AR et al. Recognizing unmet need in the era of targeted therapy for CLL/SLL: “What’s past is prologue” (Shakespeare). Clin Cancer Res 2022;28(4):603-8. Abstract
O’Brien SM et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 2021;11:720704. Abstract
Parry EM et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter’s syndrome. AACR 2022;Abstract 4007.
Roeker LE et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study. AACR 2022;Abstract CT138.
Smith CIE et al. Editorial: New insights on Bruton’s tyrosine kinase inhibitors. Front Immunol 2021;12:804735. Abstract
Tam CS et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Tedeschi A et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Early results from arm D of the SEQUOIA (BGB-3111-304) trial. ASH 2021;Abstract 67.
Wierda WG et al. Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations. Leukemia 2021;35(11):3059-72. Abstract
Zain R, Vihinen M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front Immunol 2021;12:694853. Abstract